表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）的问世开启了 EGFR 突变非小细胞肺癌（NSCLC）的精准治疗时代，特别是三代 EGFR-TKI 奥希替尼，凭借着显著的全身和颅内疗效获益，已成为此类患者的一线标准治疗方案[1-3]。然而，EGFR-TKI 单药治疗存在一定的局限性，比如存在 EGFR L858R ...

In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a priority. While the current standard of care—combining doublet chemotherapy with ...

Epidermal growth factor receptor (EGFR) signaling in the tissue around oral cancers both increases nerve sensitivity and ...

BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology ...

Background: Treatment options for lung cancer patients with epidermal growth factor receptor (EGFR) mutations are limited after tyrosine kinase inhibitor (TKI) resistance. We aimed to evaluate the ...

DM Intelligence Medicine Ltd. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin), LRRK2 (G2019S mutant) and/or EGFR (HER1; erbB1 mutant) inhibitors reported to be useful for the treatment of ...

TKIs under active clinical investigation are mostly derived from quinazoline, and are low molecular weight synthetic molecules that block the magnesium-ATP-binding pocket of the intracellular tyrosine ...

Fort Lee, NJ, March 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative ...

March 17, 2009 (Hollywood, Florida) — The management of dermatologic toxicities associated with the use of epidermal growth-factor-receptor (EGFR) inhibitors in cancer patients is in a nascent stage ...

Hetero Labs Ltd. has patented benzimidazole compounds acting as EGFR (HER1; erbB1) and its mutant inhibitors. They are reported to be useful for the treatment of cancer.